Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Avidity Biosciences Inc (NASDAQ: RNA) was $31.64 for the day, down -0.57% from the previous closing price of $31.82. In other words, the price has decreased by -$0.57 from its previous closing price. On the day, 1.32 million shares were traded. RNA stock price reached its highest trading level at $32.16 during the session, while it also had its lowest trading level at $30.96.
Ratios:
Our analysis of RNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 17.76 and its Current Ratio is at 17.76. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 20, 2024, initiated with a Buy rating and assigned the stock a target price of $72.
On November 26, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $67.
On September 24, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $59.Goldman initiated its Buy rating on September 24, 2024, with a $59 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 18 ’24 when Flanagan W. Michael sold 12,742 shares for $32.66 per share. The transaction valued at 416,154 led to the insider holds 72,647 shares of the business.
MacLean Michael F sold 11,151 shares of RNA for $364,192 on Dec 18 ’24. The Chief Financial Officer now owns 82,942 shares after completing the transaction at $32.66 per share. On Dec 18 ’24, another insider, Boyce Sarah, who serves as the President and CEO of the company, sold 31,855 shares for $32.66 each. As a result, the insider received 1,040,384 and left with 265,308 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 3774936576 and an Enterprise Value of 2215430400. For the stock, the TTM Price-to-Sale (P/S) ratio is 382.27 while its Price-to-Book (P/B) ratio in mrq is 2.50. Its current Enterprise Value per Revenue stands at 218.981 whereas that against EBITDA is -6.879.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $8.49. The 50-Day Moving Average of the stock is -24.91%, while the 200-Day Moving Average is calculated to be -14.98%.
Shares Statistics:
RNA traded an average of 1.19M shares per day over the past three months and 1623370 shares per day over the past ten days. A total of 118.90M shares are outstanding, with a floating share count of 108.48M. Insiders hold about 9.07% of the company’s shares, while institutions hold 101.10% stake in the company. Shares short for RNA as of 1732838400 were 14935394 with a Short Ratio of 12.59, compared to 1730332800 on 14659552. Therefore, it implies a Short% of Shares Outstanding of 14935394 and a Short% of Float of 15.439998999999998.
